These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2578898)

  • 41. [Pulmonary capillary blood volume and membrane components of pulmonary diffusion capacity in patients with chronic obstructive bronchitis (COPD)].
    Schulz U; Langwieler S; Riedel S; Schreiber J
    Pneumologie; 2014 Apr; 68(4):266-9. PubMed ID: 24615667
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
    Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pulmonary side effects of bleomycin therapy].
    Andler W
    Klin Padiatr; 1984; 196(1):47-8. PubMed ID: 6198554
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pulmonary diffusing capacity disturbances are related to nailfold capillary changes in patients with Raynaud's phenomenon with and without an underlying connective tissue disease.
    Groen H; Wichers G; ter Borg EJ; van der Mark TW; Wouda AA; Kallenberg CG
    Am J Med; 1990 Jul; 89(1):34-41. PubMed ID: 2368791
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Late pulmonary changes following bleomycin administration in computed tomography. Nodular fibrosis mimicking a seminoma metastasis].
    Gehl HB; Hauptmann S; Sohn M; Bohndorf K
    Radiologe; 1992 Feb; 32(2):80-2. PubMed ID: 1373509
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pulmonary diffusing capacity, capillary blood volume, and cardiac output during sustained microgravity.
    Prisk GK; Guy HJ; Elliott AR; Deutschman RA; West JB
    J Appl Physiol (1985); 1993 Jul; 75(1):15-26. PubMed ID: 8376261
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bleomycin lung injury in children. Pathophysiology and guidelines for management.
    Eigen H; Wyszomierski D
    Am J Pediatr Hematol Oncol; 1985; 7(1):71-8. PubMed ID: 2412460
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pulmonary capillary blood volume and membrane conductance in Andeans and lowlanders at high altitude: a cross-sectional study.
    de Bisschop C; Kiger L; Marden MC; Ajata A; Huez S; Faoro V; Martinot JB; Naeije R; Guénard H
    Nitric Oxide; 2010 Nov; 23(3):187-93. PubMed ID: 20573559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vinblastine, cisplatin and bleomycin treatment of advanced nonseminomatous testicular tumors.
    Bodrogi I; Baki M; Horti J; Liszka G; Ottó S; Hindy I; Sugár J; Eckhardt S
    Neoplasma; 1990; 37(4):445-50. PubMed ID: 1700311
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of corticosteroid administration on bleomycin lung toxicity.
    Jensen JL; Goel R; Venner PM
    Cancer; 1990 Mar; 65(6):1291-7. PubMed ID: 1689606
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of growth on lung transfer factor and its components.
    Mahajan KK; Mahajan SK; Mishra N
    Indian J Chest Dis Allied Sci; 1992; 34(2):77-83. PubMed ID: 1459666
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term follow-up of pulmonary function in patients cured from testicular cancer with combination chemotherapy including bleomycin.
    Lehne G; Johansen B; Fosså SD
    Br J Cancer; 1993 Sep; 68(3):555-8. PubMed ID: 7688978
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Variation in the HFE gene is associated with the development of bleomycin-induced pulmonary toxicity in testicular cancer patients.
    van der Schoot GGF; Westerink NL; Lubberts S; Nuver J; Zwart N; Walenkamp AME; Wempe JB; Meijer C; Gietema JA
    Eur J Cancer; 2016 May; 59():134-141. PubMed ID: 27033261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tallysomycin S10b--a phase I trial.
    Sørensen PG; Pedersen H; Clausen HV; Hansen HH
    Cancer Chemother Pharmacol; 1989; 24(2):113-6. PubMed ID: 2471602
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bleomycin-induced pneumonitis.
    Sleijfer S
    Chest; 2001 Aug; 120(2):617-24. PubMed ID: 11502668
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of aging and cardiorespiratory fitness on the lung diffusing capacity response to exercise in healthy humans.
    Coffman KE; Carlson AR; Miller AD; Johnson BD; Taylor BJ
    J Appl Physiol (1985); 2017 Jun; 122(6):1425-1434. PubMed ID: 28336536
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Routine pulmonary function tests during bleomycin therapy. Tests may be ineffective and potentially misleading.
    Lewis BM; Izbicki R
    JAMA; 1980 Jan; 243(4):347-51. PubMed ID: 6153225
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance.
    Puri S; Baker BL; Dutka DP; Oakley CM; Hughes JM; Cleland JG
    Circulation; 1995 Jun; 91(11):2769-74. PubMed ID: 7758183
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Computed tomography of pulmonary bleomycin toxicity.
    Mills P; Husband J
    Semin Ultrasound CT MR; 1990 Oct; 11(5):417-22. PubMed ID: 1699571
    [No Abstract]   [Full Text] [Related]  

  • 60. Bleomycin-induced pneumonitis, which occurred in a patient treated for an embryonal cell carcinoma of the left testicle.
    Haanen C
    Neth J Med; 1992 Jun; 40(5-6):316. PubMed ID: 1279444
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.